NAMS - NewAmsterdam Pharma Company N.V.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$51.33
DETAILS
HIGH:
$58.00
LOW:
$45.00
MEDIAN:
$51.00
CONSENSUS:
$51.33
UPSIDE:
141.55%
About NewAmsterdam Pharma Company N.V. (https://www.newamsterdampharma.com)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | 1956 | $1,139,142 USD |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 | $808,143 USD |
| Mayur Amrat Somaiya | Chief Financial Officer | 1974 | $770,393 USD |
| Louise Kooij | Chief Accounting Officer | 1976 | $695,419 USD |
| Juliette Audet | Chief Strategy & Business Officer | 1987 | $653,039 USD |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations | – | – |
| Marc Ditmarsch | Chief Development Officer | 1967 | – |
| Maryellen McQuade | Chief People Officer | – | – |
| Matthew Philippe | Executive VP & Head of Investor Relations | – | – |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary | 1976 | – |
| Robert W. Gunning CGMA | Principal Accounting Officer, VP & Controller | 1971 | – |